Atrian Bakers’s bread Tritordeum, made with the new cereal Agrasys, nominated to the Carrefour Innovation Awards Blog Post

A new type of bread  produced by Atrian Bakers  and made with Tritordeum,  has been nominated for the 2015 Carrefour Innovation Awards. The new type of bread will be subjected to population vote until the 21st of June. Tritordeum cereal is the first man-made cereal without genetic modification suitable for human consumption. Developed in the late 70s by a group of scientists from the Institute for Sustainable Agriculture (IAS) of the Higher Council for Scientific Research (CSIC)), and after 30 years of research, Agrasys -a spin-off company based at the Barcelona Science Park, founded by researchers from the IAS and the industry, launched the new bread to the market in April 2013.

Ordesa saw turnover grow to €112.4 millions, up 4.7%, in 2014 Blog Post

Laboratorios Ordesa today announced its results for the 2014 year, which reveal a growing trend mainly due to increased sales, cutting structural costs, implementing more efficient sales policies and consolidating foreign markets the company had opened in previous years. Since 2007, the Ordesa Group has a R&D&i center at Barcelona Science Park, from where the company actively participates in clinical studies and national and international research projects in the areas of immunology and cognitive development. The elaboration of hydrolyzed cereals, liquid milk, or the launching of the first porridge with bifidus effect, and supplemented infant formulas are some of the results from these projects. 

AWS Truepower takes part in the WindPower American Wind Energy Association fair Blog Post

One more time, AWS Truepower, one of the world’s leading consultancy firms in the field of renewables energies, is present at the Windpower fair of the American Wind Energy Association (AWEA) that is starting today and will run until Thursday at the Orange County Convention Center in Orlando (Florida). The subsidiary company for Europe and Latin America –AWS Truepower SLU– is based at the Parc Cientific de Barcelona (PCB).

Genetic “editing” a new tool to fight inherited disease Blog Post

Researchers at the Hospital Clínic, IDIBAPS, the Hospital Sant Joan de Deu and the Institute for Bioengineering of Catalonia (IBEC) have participated in a study, led by Dr. Juan Carlos Izpisúa Belmonte of the Gene Expression Laboratory at California’s Salk Institute, that uses molecular scissors to remove mitochondrial mutations in mouse eggs. In the study, published today in the journal Cell (doi: 10.1016/j.cell.2015.03.051), researchers developed a simple technique to eliminate mitochondrial mutations in eggs or embryos at an early stage of development.

Ordesa leads the Smartfoods project Blog Post

The Centre for the Development of Industrial Technology (CDTI) has granted the Smartfoods industrial research project for the development of smart food to a consortium of companies led by Ordesa from this R&D&i center at Parc Científic de Barcelona.The aim of this research is the design of foods and screening tests that will help reduce the risk of some of the most frequently occurring diseases that will cause 3 of every 4 deaths in 2020.

Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome Blog Post

Avizorex Pharma, a biopharmaceutical company developing novel therapeutics for Dry Eye Disease, has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye Syndrome (DES) with a new mechanism of action currently undergoing late-stage preclinical studies. Avizorex Pharma is an ophthalmology biotech backed by Inveready Venture Capital with headquarters in Elche (Alicante, Spain) and offices at Barcelona Science Park (PCB).

 

Inveready enters biotech Agrasys after leading an increase of capital Blog Post

Inveready has invested 500,000 euros in the biotech Agrasys, based at the Parc Cientific de Barcelona, through its capital fund Inveready Invierte Biotech II.  With this contribution, the venture capital investment group has become owner of  a stake of the company, of which Uninvest, a management company, is also part of, after having joined the group in 2008, and which, on this occasion, has materialized its support -through its R & D  Unifondo fund-  entering the venture jointly with the development partners involved in the increase of capital.